Mobocertinib (Synonyms: AP32788, TAK-788) |
| Catalog No.GC47697 |
Mobocertinib(TAK-788)은 경구 활성 및 비가역적 EGFR/HER2 억제제입니다. 모보세르티닙은 야생형 EGFR에 비해 선택적으로 활성화된 EGFRex20ins 돌연변이를 포함하는 발암성 변이체를 강력하게 억제합니다. Mobocertinib은 NSCLC 연구에 사용할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1847461-43-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mobocertinib is an inhibitor of mutant EGFR and HER2 receptors.1,2 It is selective for the HER2 exon 20 mutants HER2V659E, HER2G660D, HER2G309E, and HER2S310F over wild-type EGFR in Ba/F3 cells.1
1.Chouitar, J., Vincent, S., Brake, R., et al.TAK-788 is a novel and potent tyrosine kinase inhibitor with selective activity against EGFR/HER2AbstractsS811P2(13-32)(2018) 2.Neal, J., Doebele, R., Riely, G., et al.Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLCAbstractsS599P1(13-44)(2018)
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *